GlobeNewswire

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 Cash balance of $216.0 million on September 30, 2026, [...]
Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year
05/11/2026
FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug Discovery Innovation of the [...]
Elevar Therapeutics Announces FDA PDUFA Date for Resubmitted New Drug Application for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
05/11/2026
FDA assigns a PDUFA target action date of April 9, 2027 Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of 15.2 months FORT LEE [...]
Les données «late-breaking» sur IQIRVO® relèvent les ambitions thérapeutiques dans la CBP : plus de 85 % des patients traités obtiennent une normalisation des PAL
05/11/2026
Les résultats de l’étude ELSPIRE seront présentés en «late-breaking» lors de The Liver Meeting ® 2026 et publiés simultanément dans la revue phare de l’AASLD, HEPATOLOGY À la semaine 52, 85,3 % des patients recevant [...]
IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
05/11/2026
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting ® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY At Week 52, 85.3% of patients receiving IQIRVO ® [...]
RAMSAY SANTE : résultats intermédiaires au 30 septembre 2026
05/11/2026
COMMUNIQUÉ DE PRESSE Paris, 5 novembre 2026 Résultats trimestriels non audités à fin septembre 2026 Ramsay Santé affiche une solide performance au premier trimestre, avec une croissance continue de son chiffre d’ [...]
RAMSAY SANTE : Unaudited interim results at the end of September 2026
05/11/2026
PRESS RELEASE Paris, 5 th November 2026 Unaudited interim results at the end of September 2026 Ramsay Santé delivers solid first-quarter performance, with continued revenue growth and improved operational performance [...]
Significant growth in both revenue and earnings
05/11/2026
ANNOUNCEMENT NR. 325 5 November 2026 Trading statement for Q1 2026/27 (1 July – 30 September 2026) Significant growth in both revenue and earnings Revenue was up by 28% in Q1 2026/27 to DKK 160.0 million from DKK 124.6 [...]
GENFIT : Information financière du troisième trimestre 2026 et point sur les activités de la Société
05/11/2026
La trésorerie et les équivalents de trésorerie s’élèvent à 95,6 millions d’euros au 30 septembre 2026 et permettent un financement des activités au-delà de fin 2028. La croissance attendue des revenus futurs, combinée [...]
GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update
05/11/2026
Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company beyond 2028, with continued revenue growth and disciplined spending thereafter expected to drive GENFIT toward [...]
Scipher Medicine and Grupo Amarey Announce First PrismRA® Patient Tests Completed in Colombia
05/11/2026
DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine, a leading precision medicine company, today announced that the first patient tests under its strategic partnership with Grupo Amarey have been [...]
What Published Human Trials Show About a Postbiotic in Women Ages 40 to 55
05/11/2026
Three peer-reviewed studies behind the two ingredients in Calroy Health Sciences’ Selentra HP™ measured inflammatory markers, skin health, and bone mineral density in women during and after the menopause transition. [...]
Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
05/11/2026
Trial met primary endpoint with a statistically significant reduction in microglial activation on TSPO PET (p=0.0168) Intranasal foralumab is the first non-invasive anti-CD3 therapy that has shown a favorable safety and [...]
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
05/11/2026
Completed Phase 1 study of SCY-770, a first-in-class, highly selective, oral direct AMPK activator for the treatment of ADPKD; Phase 2 proof-of-concept trial to initiate in Q4 2026 Awarded BARDA contract providing up to [...]
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
05/11/2026
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage [...]
Prenetics’ IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics
05/11/2026
Care Bears by IM8 to launch, with great-tasting, science-backed gummy multivitamins for kids and adults in 1H 2027 Enters a global gummy supplements market projected to nearly double to ~US$47.8 billion by 2030 IM8 to [...]
Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion
05/11/2026
HINGHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, today announced that the Canadian Intellectual [...]
Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
05/11/2026
– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target –Announces [...]
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA decision for [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum